6533b850fe1ef96bd12a83a2
RESEARCH PRODUCT
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma
Sara GalimbertiMohammed Abu-rayyanAnna Grazia RecchiaGiovanna CutronaCirino BottaMoien AtrashLucio MorabitoMassimo GentileErnesto VignaMamdouh SkafiHamdi Al-janazrehMassimo MartinoFortunato Morabitosubject
Acalabrutinib; BTK; MCL; therapy; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Lymphoma Mantle-Cell; Protein Kinase Inhibitors; PyrazinesOncologymedicine.medical_specialtyLymphomaAntineoplastic AgentsLymphoma Mantle-Cell03 medical and health scienceschemistry.chemical_compound0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsAgammaglobulinaemia Tyrosine KinaseHumansMedicineBruton's tyrosine kinasePharmacology (medical)Protein Kinase InhibitorsLenalidomidePharmacologytherapy.therapybiologyAcalabrutinibbusiness.industryBortezomibStandard treatmentMCLGeneral MedicineMantle-Cellmedicine.diseaseClinical trialchemistryBTKPyrazines030220 oncology & carcinogenesisIbrutinibBenzamidesbiology.proteinAcalabrutinibMantle cell lymphomabusiness030217 neurology & neurosurgerymedicine.drugdescription
Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms 'mantle cell lymphoma' and 'acalabrutinib'. Expert opinion: Acalabrutinib has been approved for the treatment of relapsed/refractory (RR) MCL patients. To date, clinical trials have reported some adverse effects such as cardiac toxicity or atrial fibrillation. Acalabrutinib in combination with other drugs, either in chemo-containing or chemo-free schedules, represent a valid option for MCL. However, none of the treatment schedules containing BTK inhibitors have been shown to be curative in MCL. Acalabrutinib may ultimately represent an option for patients who are 'fit' and exhibit well-controlled disease, which often characterizes only a limited 'niche' among MCL patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-01-01 | Expert Opinion on Pharmacotherapy |